|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/29/19 CASI Pharmaceuticals, Inc. 10-K 12/31/18 91:7.7M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 592K
2: EX-10.20 Material Contract HTML 25K
3: EX-10.21 Material Contract HTML 31K
4: EX-10.22 Material Contract HTML 34K
5: EX-10.23 Material Contract HTML 69K
6: EX-10.24 Material Contract HTML 50K
7: EX-10.25 Material Contract HTML 152K
8: EX-10.26 Material Contract HTML 90K
9: EX-21 Subsidiaries List HTML 21K
10: EX-23.1 Consent of Experts or Counsel HTML 25K
11: EX-23.2 Consent of Experts or Counsel HTML 25K
12: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
13: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
14: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
15: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
22: R1 Document and Entity Information HTML 59K
23: R2 Consolidated Balance Sheets HTML 105K
24: R3 Consolidated Balance Sheets [Parenthetical] HTML 44K
25: R4 Consolidated Statements of Operations and HTML 65K
Comprehensive Loss
26: R5 Consolidated Statements of Stockholders' Equity HTML 77K
27: R6 Consolidated Statements of Cash Flows HTML 117K
28: R7 Description of Business HTML 60K
29: R8 Summary of Significant Accounting Policies HTML 75K
30: R9 Acquisition of Abbreviated New Drug Applications HTML 40K
From Sandoz
31: R10 Acquisition of Abbreviated New Drug Application HTML 29K
From Laurus Labs
32: R11 Investment in Equity Securities HTML 54K
33: R12 Property and Equipment HTML 61K
34: R13 Intangible Assets HTML 63K
35: R14 Establishment of Casi Wuxi HTML 27K
36: R15 Note Payable HTML 28K
37: R16 Stockholders' Equity HTML 90K
38: R17 Employee Retirement Plan HTML 28K
39: R18 Stock-Based Compensation HTML 310K
40: R19 Income Taxes HTML 173K
41: R20 Fair Value Measurements HTML 132K
42: R21 Related Party Transactions HTML 32K
43: R22 License Arrangements HTML 33K
44: R23 Commitments and Contingencies HTML 52K
45: R24 Subsequent Event HTML 27K
46: R25 Summary of Significant Accounting Policies HTML 116K
(Policies)
47: R26 Acquisition of Abbreviated New Drug Applications HTML 33K
From Sandoz (Tables)
48: R27 Investment in Equity Securities (Tables) HTML 48K
49: R28 Property and Equipment (Tables) HTML 59K
50: R29 Intangible Assets (Tables) HTML 63K
51: R30 Stockholders' Equity (Tables) HTML 76K
52: R31 Stock-Based Compensation (Tables) HTML 304K
53: R32 Income Taxes (Tables) HTML 171K
54: R33 Fair Value Measurements (Tables) HTML 116K
55: R34 Commitments and Contingencies (Tables) HTML 41K
56: R35 Description of Business (Details Textual) HTML 61K
57: R36 Summary of Significant Accounting Policies HTML 41K
(Details Textual)
58: R37 Acquisition of Abbreviated New Drug Applications HTML 27K
From Sandoz (Details)
59: R38 Acquisition of Abbreviated New Drug Applications HTML 34K
From Sandoz (Details Textual)
60: R39 Acquisition of Abbreviated New Drug Application HTML 38K
From Laurus Labs (Details Textual)
61: R40 Investment in Equity Securities (Details) HTML 29K
62: R41 Investment in Equity Securities (Details Textual) HTML 41K
63: R42 Property and Equipment (Details) HTML 36K
64: R43 Property and Equipment (Details Textual) HTML 29K
65: R44 Intangible Assets (Details) HTML 33K
66: R45 Intangible Assets (Details 1) HTML 36K
67: R46 Intangible Assets (Details Textual) HTML 23K
68: R47 Establishment of Casi Wuxi (Details Textual) HTML 34K
69: R48 Note Payable (Details Textual) HTML 35K
70: R49 Stockholders' Equity (Details) HTML 46K
71: R50 Stockholders' Equity (Details Textual) HTML 133K
72: R51 Employee Retirement Plan (Details Textual) HTML 25K
73: R52 Stock-Based Compensation (Details) HTML 31K
74: R53 Stock-Based Compensation (Details 1) HTML 35K
75: R54 Stock-Based Compensation (Details 2) HTML 70K
76: R55 Stock-Based Compensation (Details 3) HTML 61K
77: R56 Stock-Based Compensation (Details Textual) HTML 60K
78: R57 Income Taxes (Details) HTML 29K
79: R58 Income Taxes (Details 1) HTML 43K
80: R59 Income Taxes (Details 2) HTML 52K
81: R60 Income Taxes (Details 3) HTML 32K
82: R61 Income Taxes (Details Textual) HTML 45K
83: R62 Fair Value Measurements (Details) HTML 34K
84: R63 Fair Value Measurements (Details 1) HTML 32K
85: R64 Fair Value Measurements (Details Textual) HTML 27K
86: R65 Related Party Transactions (Details Textual) HTML 50K
87: R66 Commitments and Contingencies (Details) HTML 35K
88: R67 Commitments and Contingencies (Details Textual) HTML 57K
90: XML IDEA XML File -- Filing Summary XML 148K
89: EXCEL IDEA Workbook of Financial Reports XLSX 86K
16: EX-101.INS XBRL Instance -- casi-20181231 XML 2.33M
18: EX-101.CAL XBRL Calculations -- casi-20181231_cal XML 125K
19: EX-101.DEF XBRL Definitions -- casi-20181231_def XML 850K
20: EX-101.LAB XBRL Labels -- casi-20181231_lab XML 954K
21: EX-101.PRE XBRL Presentations -- casi-20181231_pre XML 971K
17: EX-101.SCH XBRL Schema -- casi-20181231 XSD 180K
91: ZIP XBRL Zipped Folder -- 0001144204-19-016832-xbrl Zip 167K
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements of CASI Pharmaceuticals, Inc. on Forms S-8 (File Nos. 333-101617, 333-222043 and 333-228980) and Forms S-3 (File Nos. 333-80193, 333-84907, 333-76824, 333-104380, 333-110604, 333-122309, 333-133190, 333-132715, 333-151542, 333-167754, 333-182803, 333-200927, 333-214889, 333-222046, 333-222701, 333-228383 and 333-226206) of our report, dated March 29, 2018 on our audit of the consolidated financial statements of CASI Pharmaceuticals, Inc., as of December 31, 2017 and for the year then ended, included in this Annual Report on Form 10-K of CASI Pharmaceuticals, Inc. for the year ended December 31, 2018.
| /s/CohnReznick LLP |
Roseland, New Jersey
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/29/19 | 8-K | ||
| For Period end: | 12/31/18 | NT 10-K | ||
| 3/29/18 | 10-K, 8-K | |||
| 12/31/17 | 10-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. (DE) 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 3/28/22 CASI Pharmaceuticals, Inc. (DE) 10-K 12/31/21 104:11M Toppan Merrill Bridge/FA 3/30/21 CASI Pharmaceuticals, Inc. (DE) 10-K 12/31/20 109:13M Toppan Merrill Bridge/FA |